Melatonin: Evidence, Label Amounts and Legal Status

Melatonin at a glance

Melatonin is the hormone the brain releases in darkness to set the timing of the body’s 24-hour rhythm. In reviews of placebo-controlled trials, it shortened the time to fall asleep by a few minutes and reduced jet lag, with no effect on strength or endurance. In the UK it is a prescription-only medicine. In the EU it is both the active substance of authorised medicines and a food ingredient with two authorised health claims.

Evidence: Human trials · Updated 19 November 2026

What melatonin is

Melatonin (5-methoxy-N-acetyltryptamine) is a hormone made mainly in the pineal gland and the retina, with smaller amounts in other tissues. Its blood level follows a daily rhythm: low in the daytime, high at night. Light at night can block its production.

Supplements can use melatonin from animals or microorganisms, but most of it is made synthetically. It comes as tablets, capsules, liquids and gummies. Prolonged-release forms, such as the medicine Circadin, release melatonin slowly over a few hours.

How it works

Melatonin works as a timing signal. Its high level at night tells tissues that carry melatonin receptors that it is night, and those tissues set their daily and seasonal rhythms by it.

The signal runs through two receptors, MT1 and MT2. Both belong to the G protein-coupled receptor family, and both are targets of sleep medicines such as ramelteon and tasimelteon.

Jet lag shows the mechanism at work. After a flight across several time zones, the body’s internal rhythms fall out of step with day and night at the destination. Melatonin has been used to bring them back in line with local time.

Evidence

Evidence label: Human trials. Our labels describe the ingredient, not a product; see how we review.

Falling asleep. A meta-analysis of 19 placebo-controlled trials in 1,683 adults and children with primary sleep disorders found that melatonin cut the time to fall asleep by 7 minutes on average. Total sleep rose by 8 minutes and overall sleep quality improved; the authors describe the effects as modest.

A 2023 meta-analysis of 22 trials in adults with insomnia disorder covered 4,875 participants, 925 of them on melatonin and the rest on ramelteon or placebo. Prolonged-release melatonin shortened the time to fall asleep by about 5 minutes measured objectively and 6 minutes as reported by participants.

Results are not uniform. A 2022 review of 24 trials in chronic insomnia found no significant effect in adults without other conditions, and an effect in children and adolescents.

Jet lag. A 2002 Cochrane review included ten placebo-controlled trials in airline passengers, airline staff and military personnel. Nine of them found that melatonin reduced jet lag after flights crossing five or more time zones.

Training performance. A 2024 meta-analysis of 19 studies in healthy people found no effect of melatonin on time-trial performance, VO2 or strength.

Use with care. Information on the long-term use of melatonin supplements is lacking. Check with a doctor before using melatonin if you take any medicine, especially a blood thinner. The same applies if you have epilepsy or liver or kidney problems, or are pregnant or breastfeeding.

Amounts on labels

Hammer Labz sells melatonin in two single-ingredient capsule products. Melatonin 5 mg lists 5 mg of melatonin per capsule, with 200 capsules per container. Melatonin Max 10 mg lists 10 mg per capsule, with 100 capsules per container. On both panels, melatonin is the only active ingredient.

Legal and anti-doping status

Status checked on 19 November 2026.

  • UK: melatonin is a medicine available only on prescription.
  • EU, medicines: melatonin is the active substance of authorised medicines. Circadin and Slenyto, both medicines for insomnia, hold EU-wide authorisations, granted in 2007 and 2018. The European Medicines Agency’s database also lists melatonin medicines authorised nationally in 24 of the 27 EU countries.
  • EU, food: EU law authorises two health claims for foods containing melatonin. One reads “Melatonin contributes to the alleviation of subjective feelings of jet lag”, the other “Melatonin contributes to the reduction of time taken to fall asleep”. Each claim may be used only under the conditions of use set in the regulation.
  • WADA: melatonin is not named on the 2026 or 2027 WADA List. If you are a tested athlete, check any supplement with your anti-doping organisation.

Status differs by country and changes over time.

Found in

Hammer Labz (brand page)

  • Melatonin 5 mg
  • Melatonin Max 10 mg

BioTech USA

  • Melatonin (90 capsules)

Haya Labs

  • Haya Labs Melatonin 4 mg
  • Melatonin Time Release 5 mg

We have not seen the BioTech USA and Haya Labs labels, so we give no amounts for them.

Sources

  1. Product labels: Hammer Labz supplement facts panels for Melatonin 5 mg and Melatonin Max 10 mg, as listed in November 2026.
  2. Dubocovich ML, Delagrange P, Krause DN, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev, 62(3), 343–380. PMID: 20605968.
  3. Liu J, Clough SJ, Hutchinson AJ, et al. (2016). MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol, 56, 361–383. PMID: 26514204.
  4. National Center for Complementary and Integrative Health (NIH). Melatonin: What You Need To Know. Last updated May 2024. Accessed 19 November 2026.
  5. Ferracioli-Oda E, Qawasmi A, Bloch MH (2013). Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One, 8(5), e63773. PMID: 23691095.
  6. Maruani J, Reynaud E, Chambe J, et al. (2023). Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: A systematic review and meta-analysis. J Sleep Res, 32(6), e13939. PMID: 37434463.
  7. Choi K, Lee YJ, Park S, et al. (2022). Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses. Sleep Med Rev, 66, 101692. PMID: 36179487.
  8. Herxheimer A, Petrie KJ (2002). Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev, (2), CD001520. PMID: 12076414.
  9. Drummond FR, Drummond LR, Campos HO, et al. (2024). Is melatonin as an ergogenic hormone a myth? a systematic review and meta-analysis. Endocrine, 83(2), 302–321. PMID: 37658244.
  10. NHS. Melatonin. Page last reviewed 6 November 2026. Accessed 19 November 2026.
  11. European Medicines Agency. Circadin: European public assessment report. Marketing authorisation issued 29 June 2007. Accessed 19 November 2026.
  12. European Medicines Agency. Slenyto: European public assessment report. Marketing authorisation issued 20 September 2018. Accessed 19 November 2026.
  13. European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 19 November 2026.
  14. European Union. Commission Regulation (EU) No 432/2012, Annex: list of permitted health claims. legislation.gov.uk version. Accessed 19 November 2026.
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 16 November 2026.
  16. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 16 November 2026.